Financing co-led by seasoned healthcare investors, CAM Capital and Polaris Partners SAN DIEGO, October 27, 2020 — Primmune Therapeutics today announced the initial closing of a $27.4 million Series A financing to advance the development of novel...
SAN DIEGO, March 31, 2020 – Primmune Therapeutics announced today that it has selected PRTX007 as its lead clinical development candidate for SARS-CoV-2 (the virus that causes COVID-19) and for oncology indications. “PRTX007 is an oral small molecule that specifically...
SAN DIEGO, March 2, 2020 – Primmune Therapeutics today announced that it has raised $7 million in seed financing to support the development of novel orally-administered, small molecule toll-like receptor 7 (TLR7) agonists for long-term systemic activation of innate...
SAN DIEGO, November 6, 2019 – Primmune Therapeutics today announced that it will present primate pharmacology data on PRX034 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2019 in National Harbor, MD. PRX034 is a novel orally bioavailable small...
SAN DIEGO, April 1, 2019 – Primmune Therapeutics today announced that it will present preclinical data on a novel series of toll-like receptor 7 (TLR7) agonists engineered for systemic activation of innate immunity at the American Association for Cancer Research...
